openPR Logo
Press release

Kinase Targeted Therapeutics Market with Current Trends Analysis 2016 - 2024

03-28-2018 03:44 PM CET | Health & Medicine

Press release from: Transparency Market Research

/ PR Agency: Transparency Market Research
Kinase Targeted Therapeutics Market with Current Trends

Kinase is a class of enzyme that helps to transfer phosphate groups to the targeted substrate from molecules with high energy such as adenosine triphosphate (ADP). Disrupted or inappropriate kinase activity has been associated with several chronic diseases such as diabetes, neurological disorders, cancer, and cardiovascular disorders.

The rising prevalence of chronic diseases such as cancer and diabetes is one of the primary factors driving the global kinase-targeted therapeutics market. The World Diabetes Foundation (WDF) estimates the number of people suffering from diabetes to reach 438 million by 2030. Similarly, the World Cancer Research Fund International projects the count of people suffering from cancer across the world to reach 21 million by the same year. Kinases vary on the basis of molecules on which they act. Some of them are lipid kinase, protein kinase, and carbohydrate kinase.

Download Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=11468

The report serves as a reliable source of analysis and data regarding various important aspects of the global kinase-targeted therapeutics market. It presents a comprehensive account of the market dynamics including trends and opportunities. It offers invaluable insights into the competitive landscape of the market. It profiles the key companies operating in the market along with their business strategies, market shares, cost and revenue structure, contact information, and latest developments. For a coherent understanding, the report categorizes the global kinase-targeted therapeutics market on the basis of various criteria including geography, and target molecules.

The continuous research and development activities in the field of life science are providing a fillip to the global kinase-targeted therapeutics market. Governments worldwide are allocating substantial budgets for medical advancements. Moreover, the improving healthcare facilities in developing countries coupled with increasing healthcare spending are augmenting the market. Since aged people are more susceptible to chronic diseases and age-related deformities, the growing geriatric population is working in favor of the market.

On the other hand, the increasing awareness regarding the side-effects of kinase-targeted therapeutics drugs is restraining the growth of the market. These drugs are hazardous to the normal functioning of the liver and critical organs such as lungs and kidneys.

Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=11468

The key segments analyzed in the report based on geography are North America, Asia Pacific, Europe, and Rest of the World. North America will account for a substantial share in the market throughout the review period owing to the presence of a large base of geriatric population. The domicile of large manufacturers of kinase-targeted therapeutic drugs is providing an edge to the region over other regions. In addition, the continuous research and development activities in the field are supporting the growth of the market in the region.

Asia Pacific is expected to exhibit significant growth during the same period. The growth of the region can be attributed to the expanding base of patients suffering from chronic diseases. The improving healthcare infrastructure along with the rising expenditure of the populace on healthcare is propelling the growth of the region.

Obtain Report Details @ https://www.transparencymarketresearch.com/kinasetargeted-therapeutics-market.html

A large number of pharmaceutical giants are investing in the area of kinase modulation, and are among the leading players in the market. Several companies operating in the global kinase-targeted therapeutics market are keen on designing and launching improved agents that target diverse combinations of kinases. They are focusing towards business development and pipeline enrichment through mergers and acquisitions. Some of the prominent manufacturers of kinase-targeted therapeutic drugs are Eli Lilly and Company, Abbott Laboratories, Avila Therapeutics Inc., Array BioPharma Inc., and Bristol-Myers Squibb Co.

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact Us

Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Kinase Targeted Therapeutics Market with Current Trends Analysis 2016 - 2024 here

News-ID: 996583 • Views:

More Releases from Transparency Market Research

Global SiC Ceramics Market Poised for Robust Growth, Projected to Reach USD 3.1 Billion by 2035 | Transparency Market Research
Global SiC Ceramics Market Poised for Robust Growth, Projected to Reach USD 3.1 …
The global silicon carbide (SiC) ceramics market continues to demonstrate strong growth potential, underpinned by accelerating demand from advanced industrial and electronic applications. Valued at US$ 1.8 Billion in 2024, the market is projected to reach US$ 3.1 Billion by 2035, expanding at a compound annual growth rate (CAGR) of 5.2% during the forecast period from 2025 to 2035. This steady expansion reflects the increasing importance of SiC ceramics as
Furfuryl Alcohol Market to Reach USD 1.34 Billion by 2035, Supported by Rising Demand for Bio-Based Chemicals and Expanding Foundry Industry | TMR
Furfuryl Alcohol Market to Reach USD 1.34 Billion by 2035, Supported by Rising D …
The global Furfuryl Alcohol Market was valued at US$ 624.3 million in 2024 and is projected to reach US$ 1,341.2 million by 2035, expanding at a compound annual growth rate (CAGR) of 7.2% from 2025 to 2035. This growth is primarily driven by the rising demand for bio-based and sustainable chemicals, along with the steady expansion of the foundry and metal casting industry, particularly across emerging economies in Asia Pacific. Gain a
Air-Entraining Agents Market Outlook 2035: Forecast to Reach US$ 2.48 Billion by 2035 at a CAGR of 3.5% Driven by Infrastructure Expansion and Climate-Resilient Concrete Demand
Air-Entraining Agents Market Outlook 2035: Forecast to Reach US$ 2.48 Billion by …
The global Air-Entraining Agents (AEAs) Market was valued at US$ 1.70 billion in 2024 and is projected to reach US$ 2.48 billion by 2035, expanding at a compound annual growth rate (CAGR) of 3.5% from 2025 to 2035. This steady growth trajectory reflects the essential role AEAs play in modern concrete formulations, particularly in infrastructure projects that demand long-term durability, freeze-thaw resistance, and improved workability. Despite being a mature segment within
A2P SMS Market Outlook 2035: Expanding from US$ 71.2 Bn in 2024 to US$ 117.0 Bn by 2035 at a CAGR of 4.2%
A2P SMS Market Outlook 2035: Expanding from US$ 71.2 Bn in 2024 to US$ 117.0 Bn …
The global Application-to-Person (A2P) SMS market is entering a phase of steady and resilient expansion, driven by the growing need for secure, reliable, and real-time communication between enterprises and consumers. Valued at US$ 71.2 Bn in 2024, the market is projected to reach US$ 117.0 Bn by 2035, expanding at a CAGR of 4.2% from 2025 to 2035. Despite the rise of internet-based messaging platforms, A2P SMS continues to maintain

All 5 Releases


More Releases for Kinase

Cancer Tyrosine Kinase Inhibitors Market Cancer Tyrosine Kinase Clinical Pipelin …
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. The Journey: Genesis to Present of Tyrosine Kinase Inhibitors 2. Tyrosine Kinase: An Overview 3. Tyrosine Kinases Inhibitors: Promising Tools for Targeted Cancer Therapies 4. Types of Tyrosine Kinase Receptors 4.1 Epidermal Growth Factor Receptor 4.1.1 Types of Epidermal Growth Factor Receptor 4.1.2 Epidermal Growth Factor Receptor & Ligands 4.1.3
Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Bet …
According to the recently published report 'Mitogen Activated Protein Kinase Kinase Kinase 7 - Pipeline Review, H1 2017'; Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Beta Activated Kinase 1 or MAP3K7 or EC 2.7.11.25) pipeline Target constitutes close to 5 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes. Request Free Sample Report - http://www.marketresearchhub.com/enquiry.php?type=S&repid=1157712 Mitogen Activated Protein Kinase Kinase Kinase 7
Tyrosine Protein Kinase JAK3 (Janus Kinase 2 or JAK3 or EC 2.7.10.2) – Pharmac …
Market Research Hub report titled ‘Tyrosine Protein Kinase JAK3 Pipeline’ (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Tyrosine-protein kinase JAK3 is an enzyme encoded by the JAK3 gene. It is involved in various processes such as cell growth, development, or differentiation. Mediates essential signaling events in both innate and adaptive immunity and plays a crucial role in hematopoiesis during T-cells development. It plays a
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Pipeline …
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) pipeline Target constitutes close to 29 molecules. Out of which approximately 29 molecules are developed by Companies. The latest report Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Pipeline Review, H1 2017, outlays comprehensive information on the Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics, complete with
Orbis Research - Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Cataly …
Description: Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) pipeline Target constitutes close to 22 molecules. Out of which approximately 20 molecules are developed by companies and remaining by the universities/institutes. The latest report Cyclin Dependent Kinase 9
Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stres …
Market Reports Center’s, ‘Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) - Pipeline Review, H2 2016’, provides in depth analysis on Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c